FDA Holds First Public Hearing on CBD

On May 31, 2019, the U.S. Food and Drug Administration (FDA) held its first public hearing on cannabidiol (CBD). The popular extract is derived from hemp or marijuana plants and has become a popular product in recent years, now found in food, beauty, oils, tinctures and other products sold in many different retail outlets including convenience and tobacconists.

Unlike marijuana, CBD contains a trace of tetrahydrocannabinol (THC) but has no psychoactive affects on the user. While there’s little research to completely confirm the findings, CBD is said to have a number of benefits and uses, from treating pain to easing the symptoms of insomnia and anxiety. The FDA, however, has concerns about CBD’s safety and how it’s marketed. Right now, the CBD market remains mostly unregulated, allowing manufacturers in the category to operate with fewer restrictions than their tobacco counterparts. The FDA has issued several CBD manufacturers warning letters in regards to certain health and marketing claims. Acting FDA Commissioner Norman Sharpless has concerns over CBD showing up in foods and drinks.

Continue Reading: Tobacco Business Magazine

Photo credit: Aphiwat chuangchoem